Quarterly Result19 May 2026, 07:51 pm
Anthem Bio FY26: Revenue ₹21,243 Mn, PAT ₹5,918 Mn
AI Summary
Anthem Biosciences Ltd announced its audited consolidated financial results for FY26 and Q4FY26. FY26 revenue from operations reached ₹21,243 Mn, with an EBITDA of ₹9,896 Mn (43.4% margin) and a PAT of ₹5,918 Mn (26.0% margin). Q4FY26 revenue stood at ₹6,109 Mn, with an EBITDA of ₹3,184 Mn (48.1% margin) and a PAT of ₹1,898 Mn (28.7% margin). The company reported a net cash position of ₹13,743 Mn as of March 31, 2026.
Key Highlights
- FY26 consolidated revenue from operations was ₹21,243 Mn.
- FY26 EBITDA reached ₹9,896 Mn with a 43.4% margin.
- FY26 PAT stood at ₹5,918 Mn, reflecting a 26.0% margin.
- Q4FY26 revenue from operations was ₹6,109 Mn.
- Q4FY26 EBITDA was ₹3,184 Mn, with a 48.1% margin.
Price Impact
More from ANTHEM